



**26<sup>th</sup> October 2009**

### **Norgine acquires cetilistat**

Norgine BV today announced that it has purchased cetilistat, a novel treatment for obesity from Alizyme Therapeutics Limited. Norgine has acquired global rights to the product, including an assignment of the existing partnering arrangement with Takeda for a cash payment and a share of certain future revenues.

Peter Stein, CEO said “We are delighted to have acquired cetilistat and look forward to integrating it into the Norgine development portfolio. We also look forward to working with our new partner Takeda and continuing the productive relationship they had previously with Alizyme.”

**ENDS**

#### **Notes to Editor**

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a direct presence in all the major European markets. In 2008, Norgine achieved its 22<sup>nd</sup> consecutive year of double-digit net product sales growth at constant exchange rates. The company employs over 1,000 people.

Norgine’s focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g., MOVICOL® for the treatment of constipation and faecal impaction, MOVIPREP® a new generation of bowel cleansing preparation, KLEAN-PREP® for bowel preparation prior to colonoscopy, XIFAXAN® for the treatment of traveller’s diarrhoea, FIVASA® for the treatment of Ulcerative Colitis and Crohn’s Disease and ORAMORPH® for the treatment of moderate to severe pain associated with cancer.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, Wales and Dreux in France.

Norgine’s web site [www.norgine.com](http://www.norgine.com)

For further information, please contact:  
Julie Hornby Winfield. Global Corporate Communications Manager  
T: +44 (0)1895 826642  
E: [jhornbywinfield@norgine.com](mailto:jhornbywinfield@norgine.com)